Trial Profile
Molecular and Genetic Changes in Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Cisplatin and Alimta - Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Jun 2017 Status changed from active, no longer recruiting to completed.
- 15 Jun 2017 Status changed from active, no longer recruiting to completed.
- 10 Jan 2014 Planned End Date changed from 1 Nov 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.